These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 15312807)
21. [Future aspects of modern Parkinson therapy]. Ransmayr G; Jeschow M Wien Med Wochenschr; 1995; 145(13):299-301. PubMed ID: 7571655 [TBL] [Abstract][Full Text] [Related]
22. The current model of basal ganglia organization under scrutiny. Parent A; Cicchetti F Mov Disord; 1998 Mar; 13(2):199-202. PubMed ID: 9539330 [No Abstract] [Full Text] [Related]
23. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033 [TBL] [Abstract][Full Text] [Related]
27. Young onset Parkinson's disease. Practical management of medical issues. Calne SM; Kumar A Parkinsonism Relat Disord; 2008; 14(2):133-42. PubMed ID: 17804273 [TBL] [Abstract][Full Text] [Related]
28. [Restoration of brain function by cell transplantation]. Kakishita K; Nakao N; Itakura T Nihon Rinsho; 2003 Mar; 61(3):457-62. PubMed ID: 12701173 [TBL] [Abstract][Full Text] [Related]
29. Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. Lansbury PT Nat Med; 2004 Jul; 10 Suppl():S51-7. PubMed ID: 15298008 [TBL] [Abstract][Full Text] [Related]
30. [Therapy of Parkinson disease. 2: New therapy concepts for treating motor symptoms]. Kuhn W; Müller T Fortschr Neurol Psychiatr; 1997 Aug; 65(8):375-85. PubMed ID: 9378450 [TBL] [Abstract][Full Text] [Related]
31. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672 [TBL] [Abstract][Full Text] [Related]
32. [Function of cortical basal nuclei: Pathophysiology of Parkinson's disease]. Takakusaki K Nihon Seirigaku Zasshi; 2003; 65(4-5):113-29. PubMed ID: 12884733 [No Abstract] [Full Text] [Related]
33. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease. Chastan N; Westby GW; Yelnik J; Bardinet E; Do MC; Agid Y; Welter ML Brain; 2009 Jan; 132(Pt 1):172-84. PubMed ID: 19001482 [TBL] [Abstract][Full Text] [Related]
34. Medical management of advanced Parkinson's disease. Goudreau JL Clin Geriatr Med; 2006 Nov; 22(4):753-72, v. PubMed ID: 17000334 [TBL] [Abstract][Full Text] [Related]
35. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies. Hodaie M; Neimat JS; Lozano AM Neurosurgery; 2007 Jan; 60(1):17-28; discussion 28-30. PubMed ID: 17228250 [TBL] [Abstract][Full Text] [Related]
37. [Atypical corticobasal degeneration with clinical pictures of Parkinson's disease--an L-dopa-effective case]. Kagamihara Y Brain Nerve; 2007 Jun; 59(6):637-45. PubMed ID: 17585597 [No Abstract] [Full Text] [Related]
38. Neurosurgery for the 21st century. What does neurobiology justify for repairing neurodegenerative disorders? Sanberg PR; Willing AE; Cahill DW Clin Neurosurg; 2001; 48():113-26. PubMed ID: 11692635 [No Abstract] [Full Text] [Related]
39. Parkinson's disease. New treatments, still no cure. Mayo Clin Health Lett; 2001 May; 19(5):1-3. PubMed ID: 11349631 [No Abstract] [Full Text] [Related]